Michael D. Huband

Experience

Michael Huband is Director of Surveillance and New Drug Development at JMI Laboratories, part of Element Materials Technology and operating as Element Iowa City. In this role, he oversees new antibacterial and antifungal surveillance, drug development, and 510K projects, including protocol design, data analysis, and medical writing encompassing abstracts, posters, reports, and publications.

Michael began his pharmaceutical research career in antimicrobial drug discovery and development in 1988 at Warner-Lambert/Parke-Davis, where he contributed to the discovery and development of enoxacin, cefdinir, clinafloxacin, and sparfloxacin. He joined Pfizer in 2000, becoming a Senior Principal Scientist in Infectious Disease Research and supporting preclinical and clinical candidates including dalbavancin, linezolid, and sulopenem. Prior to joining Element Iowa City, he served as a Principal Scientist and Team Lead at AstraZeneca Pharmaceuticals, where he contributed to the discovery and development of ceftazidime-avibactam, ceftaroline, and zoliflodacin.

Career Highlights

Over the course of his career, Michael has authored or co-authored more than 140 publications and delivered over 230 presentations at national and international meetings – a body of work that spans more than three decades of contribution to the antimicrobial field. His direct involvement in the development of agents that are now standard-of-care treatments, including linezolid (the first oxazolidinone antibiotic) and ceftazidime-avibactam (a beta-lactam/beta-lactamase inhibitor combination active against carbapenem-resistant gram-negative bacteria), reflects a career at the leading edge of infectious disease drug development.